EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

Published December 2025

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements relating to patents and licensing.

With the aim of enabling innovative plant breeding and to maintain Europe’s ability to be competitive in the International playing field, the proposal confirms that NGT-1 plants will undergo a verification process and, if they meet certain criteria, will be considered to be equivalent to a conventional plant. Only seeds and reproductive material will require to be labelled “NGT1”.  NGT2 plants and certain NGT1 plants with excluded traits will be regulated under the conventional GMO pathway.

Any form of ban on intellectual property relating to NGT plants now seems to have been firmly dismissed, which is in line with the findings of the Commissions’ study into the effect of patents relating to new genomic techniques (NGTs) on innovation in plant breeding and breeders access to genetic material. This study recognised that the EU agritech sector is structurally diverse, with many SME’s working in niche sectors alongside four multi-national players. However, a complex IP landscape and lack of transparency poses significant challenges for the SME’s in this sector, in particular in terms of the cost of freedom-to-operate analyses which may prevent them from using certain genetic material to avoid patent infringement risk. The study also recognises that the EU, being the second largest global seed market, requires IP in order to remain globally competitive. The study concluded that  “a balanced and coherent IP system is a key driver to innovation” and that facilitating licensing, rather than banning patents, is the key to fair and efficient innovation.

As such, the proposal confirms measures which aim to provide greater transparency and potential licensing standards:

  • Mandatory disclosure of patents and pending applications when applying to register an NGT-1 plants or product. Details of such patents and applications will be held in a publicly available database. However, there doesn’t appear to be any obligation to disclose PVRs.
  • Voluntary disclosure relating to the patent holder’s intention to licence the use of a patented NGT 1 plant or product, under equitable conditions.
  • Creation of a “patenting expert group” focusing on the effect of patents on NGT plants. Within a year, the Commission will publish a study on patent effects and may propose an EU Code of Conduct on licensing within 18 months, setting fair terms and dispute resolution mechanisms in cases of unintentional minor presence of patented material.

The agreement awaits formal approval, and will be applied two years after it enters into force. Whilst the scope of the patent disclosure requirement requires further clarity, IP professionals may wish to start preparing for these obligations in terms of collating patent data and considering strategies for equitable licensing.


This article was written by Partner & Patent Attorney Punita Shah.

Latest updates

Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details
Event - 15th December 2026

Basel Seminar: Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU

Venue – Der Teufelhof Basel, Switzerland We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. …

Event details
Event - 28th October 2026

HGF Attending BMCS Antibody–Drug Conjugates 2026

HGF is pleased to announce that Dr Thomas Lonsdale, Patent Director, will be attending the BMCS Antibody–Drug Conjugates 2026 meeting, taking place on 19 November 2026 at GSK, Stevenage, UK. …

Event details

Hsu Min Chung Recognised in IAM Global Leaders 2027

HGF is delighted to announce that Partner, Hsu Min Chung, has been recognised in the IAM Global Leaders 2027 guide, a prestigious ranking that highlights some of the world’s leading …

Read article
Event - 28th October 2026

HGF Attending the KINPA Conference 2026

HGF is pleased to be attending the KINPA Conference 2026, taking place on 28 October in Seoul, South Korea. Recognised as Korea’s largest intellectual property gathering, the conference brings together …

Event details
Event - 17th - 19th November 2026

HGF Attending IPBC Asia 2026

HGF is pleased to announce that Partner, Dr Jennifer Uno, will be attending IPBC Asia 2026, taking place from 17-19 November 2026 in Tokyo, Japan. The event is one of …

Event details

HGF Recognised in the Chambers and Partners UK 2027 Guide

HGF is proud to announce that we have once again been recognised in the Chambers and Partners UK 2027 Guide, with outstanding rankings for both the firm and individual practitioners …

Read article
Event - 4th November 2026

IAM Navigating the UPC conference

HGF are gold sponsors of the IAM Live Navigating the UPC conference. IAM Live: Navigating the UPC returns to Paris in November bringing together over 180 industry leaders for an …

Event details